Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Publication | Open Access

DOI Full Paper Access

649

Citations

References

2015

Year

Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon,

Journal of the American Academy of Dermatology

Autoimmune DiseaseMedicinePhase IiiClinical TrialsPlaque PsoriasisSafety TrialClinical DermatologyPharmacotherapyDermatologyPsoriatic Arthritis